ACT-541468 5 mg
DrugCapsule for oral administration containing ACT-541468 at a strength of 5 mg
NCT Number: NCT02839200
This study evaluates the dose response of ACT-541468 on the change of WASO from baseline to Days 1 and 2, assessed by PSG.
Looking for future studies?
Notify Me18 year–64 year
All sexes
Interventional
Phase 2
Investigator Site, Berlin, Germany
This study consists of the following phases: screening phase; double-blind treatment phase; safety follow-up phase. Safety is monitored throughout the study.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Principal inclusion Criteria:
Principal exclusion Criteria:
Capsule for oral administration containing ACT-541468 at a strength of 5 mg
Capsule for oral administration containing ACT-541468 at a strength of 10 mg
Capsule for oral administration containing ACT-541468 at a strength of 25 mg
Over-encapsulated zolpidem tablet at a strength of 10 mg
Placebo capsules matching ACT-541468 capsules
Placebo capsules matching over-encapsulated zolpidem
Time frame: Baseline and Days 1&2
WASO is the time in minutes spent awake after onset of persistent sleep until lights on as determined by polysomnography (PSG)
Time frame: Baseline and Days 1&2
LPS is the duration of time in minutes from lights off to persistent sleep onset as determined by PSG
Time frame: Baseline and Week 4
sLSO is the self-reported time to fall asleep, as reported in the sleep diary
Time frame: Baseline and Week 4
sWASO is the self-reported time spent awake after sleep onset as reported in the sleep diary.
Idorsia Pharmaceuticals Ltd.
Industry
Multi-center, Double-blind, Randomized, Placebo-controlled, Active-reference, Parallel-group, Polysomnography Dose-response Study to Assess the Efficacy and Safety of ACT-541468 in Adult Subjects With Insomnia Disorder
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05525637
Dyssomnias, Insomnia Disorder
Beijing, China
View Trial DetailsNCT06975514
Dyssomnias, Insomnia Disorder
Beijing, China
View Trial DetailsNCT07431034
Chronic Insomnia, Dyssomnias
Tehran, Iran
View Trial DetailsNCT06626048
Dyssomnias, Insomnia Disorder
San Francisco, California, United States
View Trial Details